Arcus Biosciences, Inc.
RCUS · NYSE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 112.00M | 112.00M | -280.00M | -267.00M | -3.71 |
| 2023 FY | 117.00M | 117.00M | -340.00M | -307.00M | -4.15 |
| 2024 FY | 258.00M | 258.00M | -330.00M | -283.00M | -3.14 |
| 2025 FY | 247.00M | 237.00M | -386.00M | -353.00M | -3.29 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 1.35B | 688.00M | 206.00M | 120.00M | 657.00M |
| 2023 FY | 1.10B | 633.00M | 127.00M | 11.00M | 462.00M |
| 2024 FY | 1.15B | 665.00M | 150.00M | 60.00M | 485.00M |
| 2025 FY | 1.14B | 508.00M | 222.00M | 112.00M | 631.00M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 438.00M | -6.00M | 432.00M | — | 58.09M |
| 2023 FY | -306.00M | -24.00M | -330.00M | — | -79.00M |
| 2024 FY | -170.00M | -6.00M | -176.00M | — | 23.00M |
| 2025 FY | -482.00M | -2.00M | -484.00M | — | 72.00M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 1.49B | 1.40B | — | — | — |
| 2023 FY | 1.41B | 1.30B | — | — | — |
| 2024 FY | 1.34B | 1.25B | — | — | — |
| 2025 FY | 2.56B | 2.45B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 160.00M | 160.00M | -8.00M | -8.00M | 0.04 |
| 2025 Q3 | 26.00M | 24.00M | -142.00M | -135.00M | -1.27 |
| 2025 Q4 | 33.00M | 30.00M | -114.00M | -98.00M | -0.92 |
| 2026 Q1 | 17.00M | 15.00M | -134.00M | -128.00M | -1.02 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 1.08B | 526.00M | 248.00M | 109.00M | 549.00M |
| 2025 Q3 | 974.00M | 538.00M | 238.00M | 111.00M | 436.00M |
| 2025 Q4 | 1.14B | 508.00M | 222.00M | 112.00M | 631.00M |
| 2026 Q1 | 997.00M | 473.00M | 201.00M | 113.00M | 524.00M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -133.00M | — | -133.00M | — | 56.00M |
| 2025 Q3 | -97.00M | — | -97.00M | — | -10.00M |
| 2025 Q4 | -120.00M | -1.00M | -121.00M | — | -16.00M |
| 2026 Q1 | -138.00M | — | -138.00M | — | -21.00M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 863.65M | 724.65M | — | — | — |
| 2025 Q3 | 1.45B | 1.32B | — | — | — |
| 2025 Q4 | 2.56B | 2.45B | — | — | — |
| 2026 Q1 | 2.71B | 2.62B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |